Financial Performance & Growth - Veracyte achieved approximately $516 million in total revenue for 2025, with a 17% testing revenue growth[12] - The company expects to achieve greater than 25% adjusted EBITDA in 2025[14] - Veracyte anticipates revenue between $570 million and $582 million in 2026, representing a 10-13% year-over-year growth[61] - The company projects a 14-16% year-over-year testing growth in 2026[61] - The company anticipates approximately 25% adjusted EBITDA margin in 2026[61] Product & Market Expansion - Over 800,000 patients have been served with Veracyte's tests to date[12] - Decipher Prostate has achieved approximately 33% market penetration in the U S[19] - Afirma has achieved approximately 38% market penetration in the U S thyroid cancer market[31] - The company plans to launch TrueMRD for muscle-invasive bladder cancer (MIBC) and Prosigna LDT in 2026[64] - Veracyte is developing IVD versions of its tests, including Decipher qPCR and Prosigna NGS, for geographic expansion[54]

Revenue Projections - Veracyte expects total revenue for Q4 2025 to be between $138 million and $140 million, with testing revenue between $134 million and $136 million[5]. - For the full year 2025, Veracyte expects total revenue between $515 million and $517 million, with testing revenue between $491 million and $493 million[5]. Testing Volume - The company anticipates testing volume of approximately 45,500 tests for Q4 2025[5]. - The projected testing volume for the full year 2025 is approximately 169,700 tests[5]. Financial Metrics - Veracyte expects an adjusted EBITDA margin of greater than 25% for the full year 2025[5]. - The company is unable to provide an estimate of net income margin for the full year 2025 due to the unavailability of reliable estimates[6]. - Key components affecting net income margin may include stock-based compensation expenses and acquisition-related expenses[6]. Financial Reporting - The preliminary financial results are subject to completion of financial closing procedures and audit adjustments[6]. - Veracyte's audited financial statements for the full year ended December 31, 2025, are not yet available[6]. - The press release regarding these results was issued on January 11, 2026[5].

Core Viewpoint - Veracyte, Inc. has announced preliminary, unaudited financial results for Q4 and the full year of 2025, indicating significant revenue growth compared to 2024 [1] Financial Results - For Q4 2025, Veracyte expects total revenue to be between $138 million and $140 million, reflecting an increase of 16% to 18% compared to the same period in 2024 [1]

Core Viewpoint - Veracyte, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 9:45 a.m. Pacific Time [1] Group 1: Company Overview - Veracyte is a leading global diagnostics company focused on transforming cancer care for patients worldwide [3] - The company empowers clinicians with high-value insights to guide patients during critical moments in cancer diagnosis and treatment [3] - Veracyte's Diagnostics Platform offers high-performing cancer tests supported by extensive genomic and clinical data, advanced bioinformatics, AI capabilities, and a robust evidence-generation engine [3] Group 2: Presentation Details - Live audio webcasts of the company's presentations will be accessible on Veracyte's website [2] - A replay of the webcast will be available for 30 days after the live broadcast concludes [2]

Core Insights - Veracyte (VCYT) is experiencing significant growth in its Afirma business line and the Decipher franchise, although macroeconomic challenges pose risks to its operations [1][11]. Financial Performance - The company has a market capitalization of $3.41 billion and an earnings yield of 3.8%, outperforming the industry's -2.6% yield [2]. - Veracyte has consistently exceeded earnings estimates over the past four quarters, with an average surprise of 45.1% [2]. Business Highlights - The Afirma solution, including the Afirma GSC and Afirma Xpression Atlas, is effectively addressing thyroid nodule diagnosis, with a 13% volume growth in Q3 2025 driven by new account wins and increased utilization [3][4][9]. - The Decipher franchise has expanded into bladder cancer, with the Decipher Bladder test being the first genomic test covered by Medicare, contributing to a total of approximately 26,700 tests performed in Q3 2025, marking 14 consecutive quarters of over 25% year-over-year volume growth [5][6][9]. - Veracyte ended Q3 2025 with cash and cash equivalents of $366 million and no debt, indicating a strong liquidity position [7][10]. Cost and Economic Challenges - The company faces macroeconomic challenges, including rising interest rates and inflation, which have led to an 11.6% year-over-year increase in total cost of revenues, with selling and marketing expenses rising by 8.1% to $24.5 million [11].

Market Overview - U.S. stock futures showed mixed results, with Dow futures decreasing approximately 0.1% on Monday [1] Company-Specific Movements - Meihua International Medical Technologies Co., Ltd. (NASDAQ:MHUA) announced its delisting from Nasdaq, leading to a significant pre-market decline of 32.9%, bringing shares down to $9.41 [1] - SMX (Security Matters) Public Limited Company (NASDAQ:SMX) shares fell 17.2% to $275.00 after a substantial increase of 135% on the previous Friday [3] - Gulf Resources, Inc. (NASDAQ:GURE) saw a decline of 16.1% to $6.87 following a 4% drop on Friday [3] - Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) shares decreased by 16.1% to $5.35 after a notable surge of 98% on Friday [3] - Fly-E Group, Inc. (NASDAQ:FLYE) experienced a 14.4% drop to $7.08 after receiving a delinquency notice from Nasdaq regarding a delayed Form 10-Q [3] - Ecarx Holdings Inc. (NASDAQ:ECX) shares fell 9.1% to $1.91 after an 8% gain on Friday [3] - Arteris Inc (NASDAQ:AIP) saw a decline of 7.1% to $16.30 in pre-market trading [3] - Veracyte Inc (NASDAQ:VCYT) shares decreased by 5.7% to $42.06 after a 6% decline on Friday [3] - Chagee Holdings Ltd (NASDAQ:CHA) shares fell 4.6% to $13.91 in pre-market trading [3] - PureTech Health PLC (NASDAQ:PRTC) experienced a 4.2% decline to $17.30, despite announcing a successful end-of-Phase 2 meeting with the FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis [3] - PepGen Inc (NASDAQ:PEPG) shares declined by 3.9% to $5.23 in pre-market trading [3]

Market Overview - U.S. stock futures showed mixed results, with Dow futures decreasing approximately 0.1% on Monday [1] Company-Specific Movements - Meihua International Medical Technologies Co., Ltd. (NASDAQ:MHUA) announced its delisting from Nasdaq, leading to a significant pre-market decline of 32.9%, bringing shares down to $9.41 [1] - SMX (Security Matters) Public Limited Company (NASDAQ:SMX) shares fell 17.2% to $275.00 after a substantial increase of 135% on the previous Friday [3] - Gulf Resources, Inc. (NASDAQ:GURE) saw a decline of 16.1% to $6.87 following a 4% drop on Friday [3] - Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) shares decreased by 16.1% to $5.35 after surging 98% on Friday [3] - Fly-E Group, Inc. (NASDAQ:FLYE) experienced a 14.4% drop to $7.08 after receiving a delinquency notice from Nasdaq regarding a delayed Form 10-Q [3] - Ecarx Holdings Inc. (NASDAQ:ECX) shares fell 9.1% to $1.91 after an 8% gain on Friday [3] - Arteris Inc (NASDAQ:AIP) saw a decline of 7.1% to $16.30 in pre-market trading [3] - Veracyte Inc (NASDAQ:VCYT) shares decreased by 5.7% to $42.06 after a 6% decline on Friday [3] - Chagee Holdings Ltd (NASDAQ:CHA) shares fell 4.6% to $13.91 in pre-market trading [3] - PureTech Health PLC (NASDAQ:PRTC) declined 4.2% to $17.30 despite announcing a successful end-of-Phase 2 meeting with the FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis [3] - PepGen Inc (NASDAQ:PEPG) shares decreased by 3.9% to $5.23 in pre-market trading [3]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum characteristics, helping investors identify stocks likely to outperform the market in the next 30 days [2][3] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - The Growth Style Score assesses a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Style Score evaluates stocks based on price trends and earnings estimate changes, aiding investors in timing their purchases [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors seeking attractive value, growth, and momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to help investors build successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.93% since 1988 [7][10] - Stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended for the highest probability of success [9] Company Spotlight: Veracyte (VCYT) - Veracyte is a diagnostics company specializing in cancer detection, offering advanced genomic tests for various cancers [11] - VCYT holds a 1 (Strong Buy) Zacks Rank and a VGM Score of B, with a Growth Style Score of B indicating a projected year-over-year earnings growth of 38.7% for the current fiscal year [12] - The Zacks Consensus Estimate for VCYT's earnings has increased by $0.23 to $1.65 per share, with an average earnings surprise of +45.1% [12][13]

Veracyte FY Conference Summary Company Overview - **Company**: Veracyte (NasdaqGM:VCYT) - **Industry**: Medtech and Diagnostics Key Financial Highlights - **Q3 Revenue**: Over $131 million, a growth of 14% year-over-year [4] - **Testing Business Growth**: Grew by 17%, with Decipher achieving over 25% growth for 14 consecutive quarters [4] - **Afirma Growth**: Volume increased by 13%, driven by new accounts and deeper penetration into existing accounts [4] - **Adjusted EBITDA**: Reached 30% for the quarter, exceeding expectations, with a forecast to finish the year over 25% [5] Decipher Product Insights - **Market Penetration**: Estimated at 40%, indicating room for growth [7] - **Durability of Growth**: Anticipated demand increase due to the recent launch of the metastatic indication and ongoing clinical trials [8][10] - **Physician Ordering Dynamics**: Changes in how tests are ordered, with a focus on building trust and integrating test ordering into clinical workflows [11][12] NCCN Guidelines Impact - **Guideline Inclusion**: The inclusion of Decipher in NCCN guidelines has provided a tailwind for growth, although isolating the impact from other factors is challenging [14] Digital Pathology and Competitive Landscape - **Digital Pathology Positioning**: Emphasized as complementary to existing tests, with a focus on avoiding confusion among clinicians [16] - **Discordance with Competitors**: Noted a 30% discordance rate between Decipher and a competing test, highlighting Decipher's validation and reliability [18][19] Future Product Developments - **V2 Transcriptome Transition**: Aiming for full transition by the end of the year, expected to enhance efficiency and reduce test failures [29][30] - **Prosigna LDT Launch**: Planned for mid-2026, with a focus on building a commercial team and engaging key opinion leaders [42][43] Market Strategy and Growth Drivers - **Growth Drivers**: Focus on Afirma, Decipher, Prosigna, MRD, and IBD, with a balanced approach to investment and growth [62] - **Market Penetration Goals**: Targeting 80% penetration in the market, currently at 65% [28] Capital Allocation and M&A Strategy - **Cash Position**: Expected to be close to $400 million with no debt, allowing for strategic investments and potential M&A opportunities [70] - **M&A Focus**: Prioritizing investments in core business areas before considering acquisitions [71] Conclusion - Veracyte is positioned for continued growth with strong financial performance, innovative product offerings, and a strategic focus on market penetration and operational efficiency. The company is actively engaging in expanding its product portfolio while maintaining a disciplined approach to capital allocation and investment in growth drivers.

Summary of Veracyte Conference Call Company Overview - **Company**: Veracyte - **Industry**: Life Sciences, specifically focused on molecular diagnostics for cancer Key Points Financial Performance - **Revenue Growth**: Total company revenue grew by 14% year-over-year in Q3 [2][3] - **Testing Business Growth**: Adjusted for a portfolio decision, the testing business grew by 18%, driven by Decipher and Afirma tests [3] - **Decipher Test Performance**: Decipher test volume grew by 26%, marking the 14th consecutive quarter of over 25% growth [3] - **Afirma Test Performance**: Afirma test volume grew by 13%, marking the 13th consecutive quarter of growth [3] - **Adjusted EBITDA Margin**: Achieved an adjusted EBITDA margin of 30%, exceeding the previously anticipated 25% [4] Product Pipeline and Future Growth - **Upcoming Products**: - Launch of an MRD test for muscle-invasive bladder cancer in the first half of 2026 [6][7] - Prosigna test to be launched as a lab-developed test (LDT) in the US, targeting 225,000 patients annually [7] - **International Strategy**: Advancing international strategy with several tests being developed for launch outside the US [7] - **Updated Transcriptome**: Transition to a new generation sequencing instrument for Afirma, expected to reduce costs and improve efficiency [9] Market Position and Competitive Landscape - **Market Penetration**: Veracyte has penetrated approximately 25% of the addressable prostate cancer market, with 75% still available for growth [11][12] - **Clinical Guidelines**: The company has achieved level one NCCN guidelines for intermediate and high-risk patients, which is expected to drive further adoption [12][25] - **Evidence-Driven Approach**: Over 240 publications support the Decipher test, enhancing its credibility and adoption among clinicians [12][27] Sales and Marketing Strategy - **Sales Team Productivity**: The sales team has shown strong productivity, with 55 sales reps and a focus on optimizing territory assignments [35][38] - **Coverage Expansion**: Currently covering 200 million lives, with expectations to increase to 250-275 million in five years, potentially improving ASP by 300-500 basis points [21] Regulatory and Reimbursement Considerations - **PAMA Analysis**: Current reimbursement rates are stable, with no immediate changes expected from PAMA until 2028 [23] - **IVD Development**: Developing a PCR-based test for Decipher to launch in Europe, leveraging existing commercial teams [42] Competitive Dynamics - **No Pricing Pressure**: The company does not currently face bundling or pricing pressure from competitors [39] Conclusion - Veracyte is positioned for continued growth with strong financial performance, a robust product pipeline, and a strategic focus on evidence-based medicine and market penetration. The company is optimistic about future launches and expanding its market share in the molecular diagnostics space.